

# Mycoviruses: Harnessing Fungal Viruses for Medical Applications and Disease Control

**Muhammad Rizwan Hamid<sup>1,2\*</sup>, Muhammad Faizan Hamid<sup>3</sup>, Shahzeen Kanwal Maria<sup>4,5</sup> and Lun He<sup>1</sup>**

<sup>1</sup>Engineering Research Center for Germplasm Innovation and New Varieties Breeding of Horticultural Crops, Key Laboratory for Vegetable Biology of Hunan Province, College of Horticulture, Hunan Agricultural University, China

<sup>2</sup>Department of Microbiology and Molecular Genetics, University of Okara, Pakistan

<sup>3</sup>University of South Asia, Cantt Campus, Lahore, Pakistan

<sup>4</sup>State Key Laboratory of Agriculture Microbiology, Huazhong Agricultural University, China

<sup>5</sup>Provincial Key Laboratory of Plant Pathology of Hubei Province, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan, China

**\*Corresponding author:** Muhammad Rizwan Hamid, Engineering Research Center for Germplasm Innovation and New Varieties Breeding of Horticultural Crops, Key Laboratory for Vegetable Biology of Hunan Province, College of Horticulture, Hunan Agricultural University, Changsha, China and Department of Microbiology and Molecular Genetics, University of Okara, Pakistan

## ARTICLE INFO

**Received:** 📅 July 07, 2023

**Published:** 📅 July 20, 2023

**Citation:** Muhammad Rizwan Hamid, Muhammad Faizan Hamid, Shahzeen Kanwal Maria and Lun He1. Mycoviruses: Harnessing Fungal Viruses for Medical Applications and Disease Control. Biomed J Sci & Tech Res 51(4)-2023. BJSTR. MS.ID.008135.

## ABSTRACT

Fungal infections continue to pose a significant burden on public health, necessitating the exploration of novel strategies for disease control. In recent years, mycoviruses, viruses that exclusively infect fungi, have emerged as potential tools for combating human fungal pathogens. This comprehensive review provides an in-depth examination of mycoviruses and their potential use as disease control agents in humans. We explore the mechanisms by which mycoviruses can reduce fungal virulence and discuss their application in antifungal therapeutics. Furthermore, we address the challenges and prospects associated with harnessing mycoviruses for disease control.

Mycovirus infections have been shown to modulate fungal virulence through the downregulation of critical virulence factors, disruption of biofilm formation, and impairment of hyphal growth. These effects contribute to a decrease in pathogenicity and host invasion. Mycoviruses hold promise as antifungal therapeutics due to their ability to specifically target and infect pathogenic fungi. Researchers have identified mycoviruses that selectively infect clinically relevant fungal pathogens, and their engineering for enhanced antifungal activity or therapeutic payload delivery shows great potential. Beyond their direct antifungal effects, mycoviruses can modulate host immune responses, enhancing the innate immune system's ability to combat fungal infections.

However, several challenges must be addressed for the successful implementation of mycoviruses as disease control agents in humans. These include optimizing delivery methods, evaluating safety concerns, and establishing regulatory frameworks. Future research should focus on further characterizing the diversity and distribution of mycoviruses in clinical settings, elucidating their interactions with host immune responses, and evaluating their efficacy in combination with existing antifungal treatments. Long-term stability and persistence of mycovirus infections in fungal populations should be investigated to assess the potential for sustained disease control. By addressing these challenges and continuing research efforts, mycoviruses may emerge as promising tools for the control of human fungal infections.

**Keywords:** Mycoviruses; Fungal Infections; Disease Control; Antifungal Therapeutics; Virulence Factors; Biofilm Formation; Hyphal Growth; Immune Responses; Delivery Methods; Safety Concerns; Regulatory Frameworks; Diversity; Distribution; Combination Therapy; Sustained Disease Control

## Introduction

### A. Overview of Fungal Infections and the Need for Innovative Disease Control Strategies

Fungal infections pose a significant threat to global health, affecting millions of individuals worldwide and imposing substantial economic burdens on healthcare systems [1]. Despite advances in medical science, the management of fungal infections remains challenging due to factors such as antifungal drug resistance, limited treatment options, and the growing incidence of immunocompromised populations. Consequently, there is an urgent need for innovative strategies to control and combat these infections effectively [1].

### B. Mycoviruses: Emerging Tools for Disease Control

In recent years, mycoviruses, which are viruses that specifically infect fungi, have gained increasing attention as potential tools for disease control [2]. Mycoviruses offer a unique approach to combatting fungal pathogens and represent a promising avenue for the development of novel antifungal therapeutics. These specialized viruses have the potential to modulate fungal virulence, disrupt key pathogenicity factors, and provide targeted antifungal activity, making them valuable assets in the fight against fungal infections.

### C. Objectives of the Review

The objective of this comprehensive review is to provide an in-depth examination of mycoviruses and their potential use as disease control agents in humans. We aim to explore the mechanisms by which mycoviruses can reduce fungal virulence, discuss their application in antifungal therapeutics, and address the challenges and prospects associated with harnessing mycoviruses for disease control.

### Mycovirus-mediated Reduction of Fungal Virulence

Mycovirus infections have been shown to modulate fungal virulence, leading to a decrease in pathogenicity and host invasion. These infections can disrupt the expression of key virulence factors in fungal pathogens, thereby attenuating their ability to cause disease and harm the host [2]. By targeting specific genes involved in fungal virulence, mycoviruses can impair the production of toxins, adhesins, proteases, and other pathogenicity factors, which are essential for fungal colonization and invasion of host tissues [3]. Furthermore, mycovirus infections have been observed to interfere with biofilm formation, a critical process for the establishment of fungal infections. Biofilms provide a protective matrix that allows fungi to adhere to surfaces and evade the host immune response [4]. Studies have shown that certain mycoviruses can disrupt biofilm formation by altering the expression of genes involved in biofilm production and maintenance, limiting the ability of fungal pathogens to persist and cause chronic infections [5].

In addition to impairing virulence factor expression and biofilm formation, mycoviruses can also inhibit hyphal growth, which is essential for fungal invasion and tissue colonization. Mycovirus-mediated

alterations in the fungal cytoskeleton or interference with signaling pathways can disrupt hyphal development, resulting in reduced fungal pathogenicity [6]. Overall, mycoviruses have demonstrated the capacity to modulate various aspects of fungal virulence, including the expression of virulence factors, biofilm formation, and hyphal growth. These effects contribute to the attenuation of fungal pathogenicity and provide potential avenues for the development of antifungal strategies targeting fungal virulence.

### Mycoviruses as Antifungal Therapeutics

Mycoviruses hold great promise as potential antifungal therapeutics due to their ability to specifically target and infect pathogenic fungi. By exploiting the natural viral-host interaction, mycoviruses offer a unique approach to combatting fungal infections and overcoming the challenges associated with traditional antifungal drugs. One of the key advantages of mycoviruses as antifungal therapeutics is their ability to provide targeted therapy. Certain mycoviruses have demonstrated a narrow host range, selectively infecting, and replicating within specific fungal pathogens while leaving non-pathogenic fungi and host cells unaffected [2]. This specificity minimizes off-target effects and reduces the risk of harming beneficial microbial communities, which is particularly important for maintaining the balance of the human microbiota.

Moreover, mycoviruses can be engineered to enhance their antifungal activity or deliver therapeutic payloads. Genetic modification of mycoviruses can be employed to enhance their ability to suppress fungal growth and virulence. For instance, researchers have successfully manipulated mycoviruses to express antifungal proteins or peptides, which can further augment their antifungal properties [7]. This approach opens possibilities for the development of novel antifungal strategies with enhanced efficacy and reduced resistance development. In addition to their direct antifungal effects, mycoviruses have the potential to stimulate host immune responses against fungal infections. Some mycoviruses have been shown to induce the production of pro-inflammatory cytokines and chemokines, promoting immune cell recruitment and activation [8]. This immune-stimulating activity can complement the antifungal effects of mycoviruses and enhance the host's ability to combat fungal infections.

Despite the significant potential of mycoviruses as antifungal therapeutics, several challenges need to be addressed for their successful implementation. Optimization of delivery methods is crucial to ensure efficient viral entry into target fungal cells while minimizing potential side effects [9]. Safety concerns, including the potential for mycoviruses to undergo genetic recombination or evolve to become more virulent, must be carefully evaluated through rigorous preclinical studies and regulatory assessments [10]. In conclusion, mycoviruses represent a promising class of antifungal therapeutics with the potential to provide targeted and effective treatment options against fungal infections. Their ability to specifically infect pathogenic fun-

gi, combined with the potential for genetic engineering and immune modulation, makes them valuable tools in the fight against fungal pathogens.

### Mycoviruses as Modulators of Host Immune Responses

In addition to their direct antifungal effects, mycoviruses have been shown to modulate host immune responses, offering a unique avenue for the control of fungal infections. By interacting with the host immune system, mycoviruses can enhance the innate immune response and contribute to the host's defense against fungal pathogens. Upon infection with mycoviruses, host cells can recognize viral components and initiate immune responses. This recognition can lead to the activation of immune cells, such as macrophages and dendritic cells, which are essential for the clearance of fungal infections [2]. Mycoviruses can also modulate the host immune response through the induction of interferon (IFN) production. Interferons are critical mediators of the antiviral immune response and can also exhibit antifungal properties. Studies have demonstrated that mycovirus infections can induce the production of type I interferons, such as IFN- $\alpha$  and IFN- $\beta$ , which play a crucial role in activating antiviral and antifungal defenses [11].

Furthermore, mycoviruses may stimulate the production of antimicrobial peptides (AMPs) by host cells. AMPs are small cationic molecules with broad-spectrum antimicrobial activity, including against fungi [12]. Several studies have shown that mycovirus infections can upregulate the expression of AMPs, enhancing the host's ability to combat fungal infections [13]. The modulation of host immune responses by mycoviruses can have implications for both antifungal defense and disease outcome. The ability of mycoviruses to stimulate immune responses and promote antiviral and antifungal defenses highlights their potential as therapeutic agents. However, the specific mechanisms underlying the immunomodulatory effects of mycoviruses and their interactions with host immune signaling pathways require further investigation.

Understanding the interplay between mycoviruses and host immune responses is crucial for harnessing the full potential of mycoviruses as modulators of the immune system. Future research should focus on elucidating the molecular mechanisms by which mycoviruses induce immune responses, identifying the viral components responsible for immunomodulation, and exploring the potential synergistic effects of mycoviruses with existing antifungal immune therapies.

### Challenges and Future Directions

Several challenges must be addressed for the successful implementation of mycoviruses as disease control agents in humans. These include optimizing delivery methods to ensure effective targeting and entry into fungal cells [2]. Additionally, safety concerns regarding potential side effects and unintended consequences of mycovirus therapy need to be thoroughly evaluated. Furthermore, regulatory approv-

al processes must be established to ensure the safe and ethical use of mycoviruses as therapeutic agents. Future research should focus on further characterizing mycoviruses, understanding their interactions with host immune responses, and exploring their potential synergistic effects with existing antifungal treatments [14]. Additionally, investigating the long-term stability and persistence of mycovirus infections in fungal populations is crucial for evaluating their efficacy as disease control agents [15].

### Conclusion

Mycoviruses hold significant promise as potential tools for disease control in humans. Their ability to modulate fungal virulence and target pathogenic fungi make them attractive candidates for antifungal therapeutics. However, further research and development are needed to overcome challenges and optimize their application in clinical settings.

### References

1. Brown Gordon D, David W Denning, Neil AR Gow, Stuart M LeVitz, Mihai G Netea, et al. (2012) Hidden killers: Human fungal infections. *Science translational medicine* 165(4): 165rv13-165rv13.
2. Xie Jiatao, Daohong Jiang (2014) New insights into mycoviruses and exploration for the biological control of crop fungal diseases. *Annual Review of Phytopathology* 52: 45-68.
3. Segers Gert C, Xuemin Zhang, Fuyou Deng, Qihong Sun, Donald L Nuss (2007) Evidence that RNA silencing functions as an antiviral defense mechanism in fungi. *Proceedings of the National Academy of Sciences* 104(31): 12902-12906.
4. Martinez Luis R, Bettina C Fries (2010) Fungal biofilms: Relevance in the setting of human disease. *Current fungal infection reports* 4: 266-275.
5. Chauhan Neeraj, Diane Inghis, Elvira Roman, Jesus Pla, Dongmei Li, et al. (2003) *Candida albicans* response regulator gene SSK, regulates a subset of genes whose functions are associated with cell wall biosynthesis and adaptation to oxidative stress. *Eukaryotic cell* 2(5): 1018-1024.
6. Ramage Gordon, Ranjith Rajendran, Leighann Sherry, Craig Williams (2012) Fungal biofilm resistance. *International journal of microbiology* 2012: 528521.
7. Liu Chenchen, Mei Li, Estifanos Tsegaye Redda, Jie Mei, Jiantai Zhang, et al. (2019) Complete nucleotide sequence of a novel mycovirus from *Trichoderma harzianum* in China. *Archives of virology* 164: 1213-1216.
8. Marzano ShinYi Lee, Leslie L Domier (2016) Novel mycoviruses discovered from meta transcriptomics survey of soybean phyllosphere phytobionomes. *Virus Research* 213: 332-342.
9. Ghabrial Said A, Max L Nibert (2009) Victorivirus, a new genus of fungal viruses in the family Totiviridae. *Archives of virology* 154(2): 373-379.
10. Al Rwahnih, MS Daubert, JR Urbez Torres, F Cordero, A Rowhani (2011) Deep sequencing evidence from single grapevine plants reveals a virome dominated by mycoviruses. *Archives of Virology* 156: 397-403.
11. Xiao Xueqiong, Jiasen Cheng, Jinghua Tang, Yanping Fu, Daohong Jiang, et al. (2014) A novel Partitivirus that confers hypovirulence on plant pathogenic fungi. *Journal of Virology* 88(17): 10120-10133.
12. Bain Judith M, Johanna Louw, Leanne E Lewis, Blessing Okai, Catriona

- A Walls, et al. (2014) *Candida albicans* hypha formation and mannan masking of  $\beta$ -glucan inhibit macrophage phagosome maturation. *M Bio* 5(6): 10-1128.
13. Nguyen Leonard T, Evan F Haney, Hans J Vogel (2011) The expanding scope of antimicrobial peptide structures and their modes of action. *Trends in biotechnology* 29(9): 464-472.
14. Kotta Loizou Ioly, Robert HA Coutts (2017) Mycoviruses in Aspergilli: A comprehensive review. *Frontiers in Microbiology* 8: 1699.
15. Hamid Muhammad Rizwan, Jiatao Xie, Songsong Wu, Shahzeen Kanwal Maria, Dan Zheng, et al. (2018) A novel delta flexi virus that infects the plant fungal pathogen, *Sclerotinia sclerotiorum*, can be transmitted among host vegetative incompatible strains. *Viruses* 10(6): 295.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2023.51.008135

Muhammad Rizwan Hamid. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



#### Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>